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Introduction 
Hydrofluoroalkane-134a (HFA) beclomethasone dipropio- 
nate (BDP) extrafine aerosol is a pressurized metered dose 
inhaler (pMD1) available for the treatment of asthma. 
Unlike most pMDIs, HFA-BDP is a solution, rather than a 
suspension, of BDP in HFA propellant. This reforrnula- 
tion, combined with improvements in inhaler technology, 
results in the production of aerosol particles of smaller 
mean mass aerodynamic diameter (MMAD) than produced 
from chlorofluorocarbon (CFC)-BDP inhalers, I.1 pm vs. 
3.5-4 pm, respectively (1,2). 
Inhaled corticosteroids are increasingly recommended for 
first-line therapy in the management of asthma (3,4) with 
pMDIs the most commonly prescribed method of delivery. 
However, a significant proportion of patients fail to use 
pMDIs correctly, even with appropriate training. It has 
been reported that 50% of patients revert to their previous 
incorrect press and breathe inhaler technique following 
proper training (5). 
HFA-BDP as the AutohalerTM (AH) inhalation device 
has been shown to be of clinical benefit to patients with 
problems handling a press and breathe pMD1 (6). Dry- 
powder inhalers (DPIs) such as the budesonide Turbuha- 
ler@ (BUD TH), have also been designed to limit the 
handling difficulties encountered with traditional pMDIs. 
However, in contrast to HFA-BDP AH, DPIs remain 
breath dependent (i.e. drug delivery from the inhaler is 
dependent on inspiratory flow) (Fig. I) (7). 
While comparative dosing strategies for HFA-BDP AH 
and BUD, TH have,‘not yet been investigated, it is 
recognized that CFC-BDP and budesonide have similar 
therapeutic efficacy and safety profiles. In the past, these 
agents have been considered to be equipotent (9,10), but 
recently budesonide has been recognized to be somewhat 
more potent, especially if administered via the Turbuhaler@ 
(3,1 I). Given this, and the fact that HFA-BDP produces 
equivalent efficacy to CFC-BDP at approximately 2.5-times 
the daily steroid dose (12) it can be hypothesized that half 
the daily dose of HFA-BDP AH would provide equivalent 
control of asthma symptoms to the BUD TH. The 
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following two studies (13,14), performed in patients with 
different severity of asthma were designed to test this 
hypothesis. Prior to the studies, all patients showed a 
defined degree of symptoms of asthma despite receiving a 
small (study I including patients with mild to moderate 
asthma) or mid-dose (study 2 including patients with 
moderate to severe asthma) of inhaled steroids. The doses 
chosen to improve symptom control were in line with 
recommendations from the global initiative for asthma 
(GINA) and normal clinical practice. 
HFA-BDP AH VS. BUD TH in patients 
with mild to moderate asthma 
In a 6-week, open label, parallel group, multicentre study 
193 patients with mild to moderate asthma (age range, l8- 
75 years) demonstrated symptomatic asthma on their 
current therapy (BUD 400pgday-‘) during 7 days prior 
to randomization to HFA-BDP AH 400 pg day- ’ (n = 98; 
baseline AM PEF 72.3% pred) or BUD TH 800pgday-’ 
(n = 95; baseline AM PEF 73.3% pred). 
Between group comparisons revealed equivalent mean 
changes from baseline for AM PEF (Fig. 2). There were no 
significant differences in asthma symptom control with 
respect to the evaluations of a daily asthma symptom score 
and a sleep disturbance score (Fig. 3). Daily /I-agonist use 
was not significantly different between both groups, 
however HFA-BDP (400pgday-‘) over 6 weeks produced 
a statistically significant reduction in total daily b-agonist 
use (PcO.05) (Fig. 4). There were no significant differences 
in the number/type of adverse events reported. On the basis 
of these results, Laitinen et al. (13) concluded that, in 
patients with mild to moderate asthma, half the daily dose 
of HFA-BDP AH (400pgday-‘) provided equivalent 
asthma control to BUD TH (800pgday-‘). 
HFA-BDP vs BUD in patients with 
moderate to severe asthma 
This was an I-week, open study in patients with moderate- 
to-severe asthma (age range, 18-75years), previously on 
500-lOOOpgday-’ CFC-BDP;. or equivalent. After 5- 
14days run in, patients were randomized to HFA-BDP 
AH 800 fig day-’ or BUD TH 1600pgday-‘. The intent- 
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FIG. 1. Flow dependence of particle size for HFA-BDP 
AH and BUD TH at two different flow rates according to 
Ross (7). MMAD’: mass median aerodynamic diameter. 
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FIG. 2. Mean change from baseline in AM PEF (I min- ‘) 
during treatment with HFA-BDP AH (400 pgday-‘) and 
BUD TH (8OOpg d-‘) according to (13). t: Significant 
within treatment group change from baseline (PcO.01); 
P 5 0.001 from equivalence. 
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FIG. 5. Mean change from baseline in AM PEF (I min-‘) 
in patients with moderate to severe asthma during 
treatment with HFA-BDP (800pgday-‘) and BUD TH 
(1600 fig day-‘). f: Significant within treatment group 
change from baseline (P<O*Ol); *: P<O.OOl equivalence. 
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FIG. 3. Mean change from baseline at weeks 5-6 in % of 
days/nights free from asthma symptoms (13). 
to-treat population consisted of I1 1 patients on HFA-BDP 
AH (mean age, 49.2years; AM PEF, 66.7% pred) and 98 
patients on BUD TH (mean age, 47.8years; AM PEF, 
67.2% pred). 
Mean change from baseline in AM PEF, at week 8 was 
23.95 I min-’ for HFA-BDP AH and 24.46 I min for BUD 
TH (Fig. 5). Furthermore, there were no significant 
differences in mean change from baseline in FEV, or 
:e 
FIG. 6. Mean change from baseline in percentage of days/ 
nights free from asthma symptoms/sleep disturbance at 
week 8, according to (14). P~0.01 within treatment group 
change from baseline (mean of the last five days of run-in 
period). Week 8: mean of the last 5 days after clinical visit 
in week 8. 
b-agonist use. Patients on HFA-BDP AH had a signifi- 
cantly greater mean change from baseline in percentage of 
days free from shortness of breath (P=O.O2), chest 
tightness (P<O*Ol) and daily asthma symptoms (P= O-03) 
at week 8 (Fig. 6). 
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TABLE 1. Incidence of adverse events possibly or probably 
related to study medication 
HFA-BDP AH BUD TH 
800 pg 1600 pg 
Adverse event (n= 111) (n=98) 
% % 
Dysphonia 
Fungal infection 
(oropharyngeal) 
54 4.1 
2,l 4.1 Leach, 1998 
60 I min-1 35 I min-I 
Borgstrom et al., 1994 
Increased asthma 
symptoms 
0 2.0 
Bronchitis 
Inhalation site 
sensation 
0 1.0 
0 I.0 
FIG. 7. Deposition of particles of HFA-BDP AH and 
BUD TH within the lung and the oropharynx (8,17). 
Stomatitis 
Glngivitis 
Weight gain 
Cough 
Inhalation taste 
sensation 
0 1.0 
0.9 0 
0.9 0 
0 0 
0 0 
The incidence, type and severity of adverse events were 
similar in each group (Table 1). At week 8, the mean change 
from baseline in corrected urine cortisol/creatinine (UCC) 
ratio in a subgroup of patients was -0.36 for HFA-BDP 
and -4.88 for BUD TH (PcO-01). In terms of systemic 
safety, the comparison of UCC ratios, which is as sensitive 
a measure as overnight urinary cortisol levels, suggested 
that there had been no clinically relevant decreases in 
cortisol levels in patients taking either medication during 
the study. The statistically significant difference of UCC- 
changes was in favour of HFA-BDP. 
study by Worth et al. (14) in patients with a greater severity 
of the disease than in the study of Laitinen er al. (13), 
asthma symptoms improved to a significantly greater extent 
in patients on HFA-BDP AH compared with patients on 
BUD TH. A possible explanation for these efficacy results 
could be differences in the lung deposition pattern of HFA- 
BDP AH and BUD TH. Improved lung deposition for 
BUD TH compared with pMD1 has been shown, especially 
when a high inspiratory flow was mandatory (8) (Fig. 6). 
For BDP, reformulation of BDP in HFA propellant has 
enhanced drug delivery to the lung periphery, independent 
of inspiratory flow (I 7). This phenomenon arises through a 
combination of factors attributable to the newly designed 
inhaler technology: particles from HFA-BDP have a 
smaller mass median aerodynamic diameter (MMAD) than 
those produced from CFC-BDP pMD1 or BUD TH, and 
the spray is more gentle than in other pMDIs (7,18). 
Therefore, according to inhaled particle dynamics, less drug 
should impact on the throat during inhalation and more 
drug should be capable of penetration to the small airways 
(Fig. 7). 
Discussion 
To improve drug delivery and therapeutic effectiveness in 
patients with asthma who have difficulty handling a pMD1, 
breath-actuated inhalers, such as the HFA-BDP AH, and 
breath-dependent DPIs, such as BUD TH, have been 
designed. 
Both studies looked at whether half the daily dose of 
HFA-BDP AH produced equivalent control of asthma 
compared with BUD TH. While the pharmacokinetics and 
biochemical properties of BUD and BDP are diverse, both 
agents are commonly used inhaled steroids in the treatment 
of asthma (15). Both treatments produced within treatment 
group improvement from baseline AM PEF during the 
course of the studies, being statistically equivalent for 
HFA-BDP AH (400 as well as 800 pg day - ‘) and BUD TI-I 
(800 as well as 1600pgday-‘). 
With regards to tolerability, HFA-BDP AH and BUD 
TH had similar profiles of side effects profiles in both 
studies. In all patients under study, drug-related events were 
predominantly mild-to-moderate in nature and low in 
frequency. A .statistically significant difference was ob- 
served, in favour of HFA-BDP AH, between mean change 
from baseline in corrected UCC at week 8 in a subgroup of 
the study of Worth et al. (14). The clinical advantage of this 
finding remains uncertain. 
In conclusion, HFA-BDP AH at half the daily dose of 
BUD TH produced equivalent improvement in control of 
asthma with additional benefits on reduction of asthma 
symptoms. 
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